What is the recommended diagnostic work‑up and management plan for a child with microcephaly?

Management Plan for Microcephaly Patient

Begin with a systematic diagnostic work-up that prioritizes identifying treatable causes and genetic etiologies, starting with detailed perinatal history, brain MRI, chromosomal microarray analysis (CMA), and targeted infectious disease testing based on clinical clues.

Initial Clinical Assessment

Critical History Elements

• Perinatal history: Document maternal fever, rash, teratogen exposure (alcohol, drugs), birth complications, placental insufficiency, and postnatal injuries 1
• Family pedigree: Three-generation analysis looking for consanguinity, recurrence patterns, and inheritance patterns (autosomal dominant, recessive, X-linked) 1
• Growth parameters: Serial measurements of head circumference, height, and weight—deceleration of head growth even within normal limits may be the only early clue 2
• Associated features: Dysmorphic features, congenital abnormalities outside CNS, skin lesions, and body asymmetries all point toward genetic causes 1

Mandatory Physical Examination Components

• Ophthalmological examination: Up to 48% of microcephaly patients have eye abnormalities including chorioretinal lacunae (Aicardi syndrome), chorioretinopathy (KIF11-related), microphthalmia/cataracts (Warburg Micro syndrome), or chorioretinitis (congenital infections) 1
• Neurological assessment: Screen for cerebral palsy (20%), epilepsy (40%), and developmental delays (~50%) 3
• Hearing evaluation: Essential given association with congenital CMV and other TORCH infections 1

Diagnostic Testing Algorithm

First-Tier Testing (Order Immediately)

1. Brain MRI (NOT CT) 3

• Yield: 43-80% will show abnormalities 3
• Look specifically for:
  • Calcifications: Suggest fetal injury or congenital infection 1
  • White matter hyperintensities: Highly suggestive of congenital CMV 1
  • Gliosis, cysts: Indicate fetal brain injury 1
  • Polymicrogyria: Can be genetic OR acquired from fetal injury 1
  • Leukoencephalopathy: Consider peroxisomal disorders 1

2. Chromosomal Microarray Analysis (CMA) 1, 4

• First-line genetic test for all unexplained microcephaly
• Detects CNVs including 22q11.2 deletion, 1p36 deletion, and submicroscopic abnormalities 1
• Genetic yield: 15.5-53.3% depending on severity 3

3. Infection Screening (If Clinical Suspicion)

• Congenital CMV testing: Retrieve Guthrie neonatal blood spot for CMV PCR if available 1
  • Suspect if: microcephaly + sensorineural hearing loss + white matter changes + calcifications 1
  • CMV accounts for 12-30% of polymicrogyria cases 1
• TORCH panel: If chorioretinitis, calcifications, or maternal history of fever/rash 1
• Zika virus serology: If maternal travel history or endemic area exposure 1

Second-Tier Testing (If First-Tier Negative)

4. Metabolic Screening (If Clinically Indicated)

• Very long chain fatty acids (VLCFAs): If child appears "too sick" for static brain malformation, has dysmorphic features, hepatomegaly, profound hypotonia, or severe leukoencephalopathy on MRI 1
• Consider peroxisomal disorders (Zellweger syndrome, D-bifunctional protein deficiency) 1

5. Fragile X Testing 4

• Particularly in males with family history suggestive of X-linked inheritance

6. Targeted Gene Testing (Based on Phenotype)

• WDR62: Most common gene for polymicrogyria with microcephaly 1
• MECP2: For females with microcephaly and developmental regression 4
• X-linked panel: If family history suggests X-linked pattern 4

Third-Tier Testing (If Still Undiagnosed)

7. Exome Sequencing (ES) or Whole Genome Sequencing (WGS) 4

• Recommended as first- or second-tier test per 2021 ACMG guidelines for unexplained developmental delay/intellectual disability with congenital anomalies 4
• Consider trio-based sequencing (patient + both parents) to identify de novo mutations 1
• May require deep sequencing to detect mosaic variants 1

8. Karyotype Analysis 1

• Consider if above testing unrevealing
• Detects balanced translocations and ring chromosome abnormalities (rare but reported) 1

Common Diagnostic Pitfalls

Critical Warnings

• Non-genetic causes account for ~30% of cases: Don't assume all microcephaly is genetic—always investigate teratogen exposure, infections, and perinatal injuries 1
• Polymicrogyria can be acquired: Presence of cortical malformations doesn't automatically mean genetic cause—vascular disruption, CMV, and other infections can cause identical imaging findings 1
• Pseudo-TORCH syndrome: COL4A1/COL4A2 variants can mimic congenital infection with calcifications 1
• Negative infection testing doesn't exclude it: Negative maternal history cannot reliably rule out teratogen exposure or infections 1

Management and Monitoring

Multidisciplinary Referrals

Based on the evidence, children with microcephaly require an average of 8 specialist referrals 5:

• Neurology (epilepsy management—41% develop seizures) 5
• Ophthalmology (37% have visual impairment) 5
• Audiology (24% have hearing loss) 5
• Developmental pediatrics/rehabilitation (66% have motor delay) 5
• Feeding specialists (68% have feeding problems) 5
• Genetics (for counseling and ongoing evaluation)

Prognostic Considerations

• Severe microcephaly (<-3 SD): ~80% have imaging abnormalities and more severe developmental impairments; 14% mortality before 12 months 3, 5
• Mild microcephaly (-2 to -3 SD): ~40% have imaging abnormalities with better outcomes 3
• Preterm birth increases risk 7.7-fold 5
• British Asian ethnicity has 3.6-fold increased risk 5

Genetic Counseling

• Accurate recurrence risk can only be provided once etiology is identified 1
• If cause remains unknown after complete work-up (occurs in 19-41% of cases), provide empirical risk based on specific phenotype and excluded causes 1, 6, 5
• All inheritance patterns (AD, AR, XL, mitochondrial, postzygotic mosaic) should be discussed when etiology unknown 1

Evidence Quality Note

The 2020 Nature Reviews Neurology international consensus guidelines 1 represent the highest quality evidence for diagnostic work-up, supplemented by recent society guidelines from ACMG and AAP 4 for genetic testing algorithms. The research studies 7, 6, 3, 5 confirm diagnostic yields and outcomes but the guideline recommendations take precedence for clinical decision-making.